GLP-1 Receptor Agonists Linked to Lower Mortality and Hospitalization in Cancer Patients

Overview

In patients with type 2 diabetes and active cancer, treatment with GLP-1 receptor agonists (GLP-1RAs) was associated with significantly reduced all-cause mortality and hospitalization rates compared to metformin. Secondary benefits included lower incidences of sepsis, major adverse cardiovascular events, pulmonary embolism, and pneumonia.

Background

GLP-1 receptor agonists improve glycemic control by enhancing insulin release and suppressing glucagon, which may be particularly beneficial in cancer patients due to the role of glucose metabolism in tumor progression. While metformin has established benefits in patients with diabetes and cancer, the effects of GLP-1RAs in this population are less well characterized. Preclinical studies suggest GLP-1RAs inhibit tumor growth via downregulation of cellular proliferation pathways. This study evaluates the impact of GLP-1RAs on survival and hospitalization outcomes in patients with type 2 diabetes undergoing cancer treatment.

Data Highlights

Key Findings

• GLP-1RA use was associated with a 12.5% reduction in all-cause mortality compared to metformin in the overall cohort.
• Patients newly started on GLP-1RAs showed a 21.4% reduction in mortality compared to those newly started on insulin.
• GLP-1RA treatment correlated with lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism, and pneumonia.
• Subanalyses stratified by body mass index and HbA1c levels did not reach statistical significance.
• GLP-1RAs may exert antitumor effects through downregulation of cellular proliferation pathways and improved glycemic control.

Clinical Implications

GLP-1 receptor agonists may offer survival and hospitalization benefits for patients with type 2 diabetes undergoing cancer treatment, potentially providing an advantage over metformin monotherapy. Clinicians should consider GLP-1RAs as part of the antihyperglycemic regimen in this population, while awaiting further prospective studies to confirm these findings.

Conclusion

GLP-1RAs are associated with improved survival and reduced hospitalization rates in patients with diabetes and active cancer compared to metformin. These findings support further investigation into GLP-1RAs as a therapeutic option in this high-risk population.

References

1. Chiang et al. 2023 -- Association of GLP-1 Receptor Agonists with Lower All-Cause Mortality and Hospitalization Rates in Cancer Patients